#MedSky🧪#PedSky#Childhoodcancer#tovorafenib#glioma#BRAFwww.cancer.gov/news-events/...

BRAF-Targeted Drug Approved for Pediatric Low-Grade Glioma

FDA has granted an accelerated approval to tovorafenib (Ojemda) for kids and teens who have low-grade glioma with changes in the BRAF gene.

The approval applies to tumors that can’t be completely removed with surgery or have come back after surgery.The approval applies to tumors that can’t be completely removed with surgery or have come back after surgery and Rx shrank or completely eliminated tumors in nearly 70% of patients.